- $15.57bn
- $14.73bn
- $2.32bn
Brief: Exelixis And Merck Sign Clinical Development Collaboration
Health Rounds: Older eggs may be made suitable for IVF
Brief: Exelixis Presents Final Overall Survival Results From Phase 3 Contact-02 Pivotal Study
Exelixis Inc reports results for the quarter ended in June - Earnings Summary
Brief: Exelixis Q2 Revenue USD 637.2 Million Vs. IBES Estimate USD 465 Million
Exelixis Inc expected to post earnings of 30 cents a share - Earnings Preview
Brief: Exelixis Announces Settlement Of Cabometyx (Cabozantinib) Patent Litigation With Cipla Limited And Cipla USA
U.S. RESEARCH ROUNDUP- Air Products and Chemicals, Geron, PayPal
Exelixis Inc reports results for the quarter ended in March - Earnings Summary
Brief: Exelixis Q1 Revenue USD 425 Million Vs. IBES Estimate USD 460.6 Million
Exelixis Inc expected to post earnings of 24 cents a share - Earnings Preview
Exelixis Inc reports results for the quarter ended in December - Earnings Summary
Brief: Exelixis Q4 Revenue USD 480 Million Vs. IBES Estimate USD 480.2 Million
Exelixis Inc expected to post earnings of 21 cents a share - Earnings Preview
Brief: Exelixis And Arcus Biosciences Announce Clinical Trial Collaboration To Evaluate Zanzalintinib In Combination With Ab521
Brief: Exelixis Announces Initiation Of Stellar-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib In Combination With Pembrolizumab
Brief: Exelixis And Arcus Biosciences Announce Clinical Trial Collaboration To Evaluate Advanced Renal Cell Carcinoma Drug
Exelixis Inc reports results for the quarter ended in September - Earnings Summary
Brief: Exelixis Q3 Revenue USD 471.9 Million Vs. IBES Estimate USD 473.6 Million